N-(1H-Indazol-3-yl)-butyramide | 82215-96-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 英文名称: N-(1H-Indazol-3-yl)-butyramide
• 英文别名: N-(1H-indazol-3-yl)butanamide
• CAS: 82215-96-1
• 化学式: C₁₁H₁₃N₃O
• 分子量: 203.244
• InChiKey: RVWAZXOEPGFVQF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  57.8
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  2-氨基苄氨肟 在 sodium ethanolate 作用下， 以 乙醇 为溶剂， 反应 23.0h， 生成 N-(1H-Indazol-3-yl)-butyramide
  参考文献：
  名称：

  Korbonits, Dezsoe; Kanzel-Szvoboda, Ida; Horvath, Karoly, Journal of the Chemical Society. Perkin transactions I, 1982, p. 759 - 766

  摘要：

  DOI：

文献信息

• Aminoindazole derivatives and intermediates, preparation thereof, and pharmaceutical compositions thereof
  申请人：——

  公开号：US20040014802A1

  公开（公告）日：2004-01-22

  The present invention relates to the novel indazole derivatives of general formula (I): 1 in which: R is either O, S or NH; R3 is an alkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, aryl, heterocycle, cycloalkyl, alkenyl, etc. radical; these radicals being optionally substituted with one or more substituents; R4, R5, R6 and R7 are chosen, independently of each other, from the following radicals: hydrogen, halogen, CN, NO 2 , NH 2 , OH, COOH, C(O)OR8, —O—C(O)R8, NR8R9, NHC(O)R8, C(O)NR8R9, NHC(S)R8, C(S)NR8R9, SR8, S(O)R8, SO 2 R8, NHSO 2 R8, SO 2 NR8R9, trifluoromethyl, trifluoromethoxy, alkyl, alkoxy, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocycle, cycloalkyl, alkenyl, etc.; these radicals being optionally substituted with one or more substituents.

  本发明涉及一般式(I)的新型吲唑衍生物： 1 其中：R为O、S或NH；R3为烷基、芳基、芳基烷基、杂芳基、杂芳基烷基、芳基、杂环、环烷基、烯基等基团；这些基团可以选择性地被一个或多个取代基取代；R4、R5、R6和R7分别选择自以下基团：氢、卤素、CN、NO 2 、NH 2 、OH、COOH、C(O)OR8、—O—C(O)R8、NR8R9、NHC(O)R8、C(O)NR8R9、NHC(S)R8、C(S)NR8R9、SR8、S(O)R8、SO 2 R8、NHSO 2 R8、SO 2 NR8R9、三氟甲基、三氟甲氧基、烷基、烷氧基、芳基、芳基烷基、杂芳基、杂芳基烷基、杂环、环烷基、烯基等；这些基团可以选择性地被一个或多个取代基取代。
• Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
  申请人：Martina Katia

  公开号：US20060106083A1

  公开（公告）日：2006-05-18

  Compounds which are indazole derivatives and pharmaceutically acceptable salts thereof, together with pharmaceutical compositions comprising them, as well as combinatorial libraries of indazole derivatives, as set forth in the specification, are disclosed; these compounds or compositions may be useful in the treatment of diseases caused by and/or associated with an altered protein kinase activity such as cancer, cell proliferative disorders, Alzheimer's disease, viral infections, auto-immune diseases and neurodegenerative disorders.

  这些是关于吲唑衍生物及其药用盐的化合物，以及包含它们的药物组合物，以及吲唑衍生物的组合化合物库的说明；这些化合物或组合物可能在治疗由改变的蛋白激酶活性引起和/或与之相关的疾病方面有用，如癌症、细胞增殖紊乱、阿尔茨海默病、病毒感染、自身免疫疾病和神经退行性疾病。
• [EN] AMINOINDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM<br/>[FR] DERIVES D'AMINOINDAZOLE AGISSANT COMME INHIBITEURS DE KINASE, METHODE D'OBTENTION ET COMPOSITIONS PHARMACEUTIQUES LES RENFERMANT
  申请人：PHARMACIA ITALIA SPA

  公开号：WO2003097610A1

  公开（公告）日：2003-11-27

  Compounds which are indazole derivatives and pharmaceutically acceptable salts thereof together with pharmaceutical compositions comprising them, as well as combinatorial libraries of indazole derivatives, as set forth in the specification, are disclosed; these compounds or compositions may be useful in the treatment of diseases caused by and/or associated with an altered protein kinase activity such as cancer, cell proliferative disorders, Alzheimer's disease, viral infections, auto-immune diseases and neurodegenerative disorders.

  本发明公开了吲唑衍生物化合物及其药学上可接受的盐，以及包括它们的制药组合物，以及吲唑衍生物的组合化学库，这些化合物或组合物可能有用于治疗由于和/或与蛋白激酶活性改变相关的疾病，如癌症，细胞增殖性疾病，阿尔茨海默病，病毒感染，自身免疫疾病和神经退行性疾病。
• Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them
  申请人：——

  公开号：US20040254177A1

  公开（公告）日：2004-12-16

  Compounds which are 3-aminoindazole derivatives or pharmaceutically acceptable salts thereof, together with pharmaceutical compositions comprising them are disclosed; these compounds or compositions are useful in the treatment of diseases caused by and/or associated with an altered protein kinase activity such as cancer, cell proliferative disorders, Alzheimer's disease, viral infections, auto-immune diseases and neurodegenerative disorders.

  本发明揭示了3-氨基吲唑衍生物或其药学上可接受的盐，以及包含它们的制药组合物。这些化合物或组合物在治疗由蛋白激酶活性改变引起和/或相关的疾病方面具有用途，例如癌症、细胞增殖性疾病、阿尔茨海默病、病毒感染、自身免疫性疾病和神经退行性疾病。
• Korbonits, Dezsoe; Kolonits, Pal, Acta Chimica Hungarica, 1990, vol. 127, # 6, p. 795 - 802
  作者：Korbonits, Dezsoe、Kolonits, Pal

  DOI：——

  日期：——